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Serum samples from 72 patients with established carcinoma of the breast were 
investigated for ectopic presence of hPL. Further, the relationship of ectop- 
ically-secreted hPL and hCG-P in breast cancer was investigated. Ten of 72 
patients examined had detectable hPL and 12 had detectable hCG-P, at 1-2 
ng/ml serum sensitivity of the assay. The presence of hPL in serum of breast 
cancer patients was found to be independent of that of hCG-P. Sera of 13 
patients with cystic mastitis, five with fibroadenoma, two with acute inflamation 
of breast, 20 normal women (non-pregnant) and 20 normal men did not show 
any detectable serum hPL or hCG-P at the above mentioned sensitivity of the 
assay. Since these hormones were not detectable in normal men, normal non- 
pregnant women, and in patients having other pathological conditions of 
breast, the possible use of them as markers in cancer is expected. 
Cancer 39:1693-1699, 1977. 
N THE PAST FEW YEARS CONSIDERABLE ATTEN- 
tion has been given to studying the secretion 
as well as of specific placental hormones 9-11~1b 
other placental proteins" as markers for the 
presence of cancer. hCG (Human Chorionic 
Gonadotrophin) and hPL (Human Placental 
Lactogen) are two such protein hormones, 
which are normally synthesized and secreted by 
syncytiotrophoblastic cells of placenta. Studies 
on ectopic secretion of hPL by non-trophoblastic 
tumors are very f e ~ . ~ + ' ~ ~ ' ~ ~ ' ~ ~ ' ~  Weintraub and 
Rosen'' reported ectopic secretion of hPL in a 
patient with bronchogenic carcinoma. Wein- 
traub and Rosen"further detected hPL in 11 of 
128 patients with various tissue proved malig- 
nancies other than those originating in tropho- 
blast or gonad. 
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Recently utilizing a radioimmunoassay, 
which selectively measures hCG in the presence 
of physiological levels of hLH (Human Luteiniz- 
ing Hormone), we have reported 13% (9/65) 
incidence of ectopic secretion of hCG-P among 
patients with established cancer of breast. It is 
now established that reagents used for the esti- 
mation of hCG-P react with intact hCG as well 
as with hCG-P. For a 50% inhibition com- 
parable to hCG-P, intact hCG required 4.3 
times more mass, in the assay system employed 
by us.' In  the present communication, we have 
scanned the serum samples of breast cancer 
patients to study whether any of the breast tu- 
mors secretes hPL; and if so we wanted to study 
the incidence of hPL secreting breast tumors. 
The same serum samples were also analyzed for 
the presence of hCG-P, with a view to find out if 
there is a concordance or discordance of hPL 
and hCG secretion by these tumors. 
MATERIALS AND METHODS 
Clinical Material and  Assessment of Cases 
Serum samples from 72 patients with estab- 
lished cancer of breast, 13 patients with chronic 
mastitis, five patients with fibroadenoma, four 
patients with gynecomastia, two patients with 
acute inflamation of breast and two male 
patients with cancer of breast were collected 
from the clinic of the Tata Memorial Hospital, 
Bombay. Histopathological diagnosis was car- 
ried out at the pathology department of the hos- 
pital. Blood samples from 20 normal non-preg- 
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TABLE 1.  Human Placental Lactogen and Human Chorionic 
Gonadotropin in Serum of Women with Various Pathological 
Conditions of Breast and of Control Men and Women 
Number of Number of 
positive positive 
cases for cases for 
Number of hPL and hCG-8 
Diagnosis studied serum serum 
cases ng/ml ng/ml 
Carcinoma of Breast 72 10 12 
Cystic Mastitis 13 Nil Nil 
Fibroadenoma 5 Nil Nil 
Gynecomastia 4 Nil Nil 
2 Nil Nil Acute inflammation 
2 Nil Nil Cancer of breast 
20 Nil Nil Normal non-pregnant 
Normal male 20 Nil Nil 
(3-5 ng/ml) (3-25 ng/ml) 
of breast 
(male) 
female 
nant women and 20 normal men were also 
collected as controls. In all the above cases oc- 
currence of pregnancy was ruled out (Table 1 ). 
Serum samples were collected on the initial 
presentation of the case at the hospital clinic 
regardless of the stage of the disease. The clini- 
cal staging (Table 5) and measurements of the 
size of the tumor mass, etc. in Tables 2 and 3 
refer to the observations made on the date of the 
collection of the serum, usually prior to starting 
any treatment. No active treatment was going 
on at the time of collection of the samples, al- 
though some of the patients had received some 
treatment such as biopsy, surgery or radio- 
therapy earlier at other institutions and pre- 
sented themselves for the first time with recur- 
rent or a residual disease. 
Age: The ages recorded also refer to the age on 
the date of collection of serum and they are 
tabulated in age groups 31 to 40; 41 to 50; 51 to 
60 and 61 to 70 as in Tables 4 and 5. 
Menstrual Status 
Menstrual status is grouped either as cyclic 
if the woman had regular cycles, menopausal if 
the periods had stopped for about 2 years and 
post-menopausal if the cycles had ceased for 
more than two years. Tables 2 and 3 give the 
clinical data on those cases which were positive 
for hPL or hCG-P. 
Staging 
Tables 2 and 3 also give TNM classification of 
the carcinoma cases as observed at the time of 
collection of the samples." In addition we have 
also included clinical staging (Table 5) into 
stages I and IV as per the classification given by 
UICC and American Joint Committee on Can- 
cer staging and end results reporting. I' 
It was felt that in a study such as this an 
estimation of the total secreting volume was im- 
portant and that the rough estimation of the 
total tumor mass might provide a better crite- 
rion of reference. Accordingly all these tumors 
have been grouped as either of small, moderate 
or large tumor volumes. 
If at the initial clinical assessment the longest 
diameter of the tumor was 5 cm or less it was 
classified as of small volume, thus including 
TABLE 2. Serum hPL in Individual Patients with Carcinoma of Breast 
Clinical Tumor hPL ng/ml 
No. Age Menstrual status Histopathology T N M class* stage* volume serum 
1. 25 menopausal Carcinoma (non- TdNi IV Moderate 5 
2. 32 cyclic (13 days)* 1nf.duct.car.' grade 31° T Z a l b + M o  I 1  Small 5 
3. 62 postmenopausal 1nf.duct.car. grade 2 T,.N,-M, I Small 4 
4. 56 postmenopausal Carcinoma (non- T 4 f i 1 M 0  111 Large 3 
5. 50 postmenopausal Carcinoma (non- T4.NsMo 111 Large 3 
6. 43 cyclic (19 days) 1nf.duct.car. grade 3 TJVl.+M, I1 Moderate 3 
7. 38 cyclic (15 days) 1nf.duct.car. grade 3 TJ'J2+Ml I11 Large 3 
8. 32 menopausal 1nf.duct.car. grade 3 T4,NNM, 111 Large 3 
9. 40 cyclic (9 days) 1nf.duct.car. grade 3 TJ'Jl.+M, 111 Large 3 
10. 45 menopausal 1nf.duct.car. grade 3 TJVl.+M, 11 Moderate 3 
(oophrectomy 6 specified) 
months) 
specified) 
specified) 
(oophorectomy 2 
months) 
Clinical assessment is described as in the text. 
+ 1nf.Duct.Car. stands for Infiltrating duct carcinoma. 
t Denotes the number of the day of the menstrual cycle. 
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TABLE 3. Serum hCG-6 Levels in Individual Patients with Carcinoma of Breast 
Clinical hCG-/3 ng/ml 
No. Age Menstrual status Histopathology T N M Class* stage* Tumor volume serum 
1.  35 Cyclic (8 days)' Carcinoma T d N O  111 Large 25 
2. 50 Postmenopausal Carcinoma T 4 A " o  111 Large 6 
3. 46 Menopausal Carcinoma T 1.N 1.M o I1 Small 6 
4. 50 Postmenopausal 1nf.duct.car.t grade 31° Tl,N,,M, I Small 8 
5. 75 Postmenopausal 1nf.duct.car. grade 3 TJVlb+MO 11 Small 8 
(non-specified) 
(10years) (non-specified) 
(non-specified) 
6.  55 Menopausal 1nf.duct.car. grade 3 T,$I$VI, I Moderate 3 
7. 48 Menopausal 1nf.duct.car. grade 3 T,$INM, I11 Large 3 
8. 56 Postmenopausal 1nf.duct.car. grade 3 T,JVo-Mo I Small 4 
9. 50 Postmenopausal 1nf.duct.car. grade 3 T,$12Mo 111 Large 3 
10. 35 Menopausal Carcinoma T,cN&fi IV Large 3 
11. 65 Postmenopausal 1nf.duct.car. grade 3 T4$I,.M1 IV Moderate 3 
12. 68 Postmenopausal Carcinoma T d i a M o  I1 Small 3 
(oophorectomy 3 
months) 
(10 years) 
(7 years) 
(1 year) (non-specified) 
(non-specified) 
* Clinical assessment is described as in the text. 
+ Denotes the number of the day of the menstrual cycle. 
1nf.Duct.Car. stands for Infiltrating duct carcinoma.'O 
most of the cases of T, and T, of TNM classifica- 
tion. 
If the longest tumor diameter was more than 5 
cm but less than 10 cm it was classified as of 
moderate tumor volume. These cases mostly 
were of T, of T N M  classification. 
Large growths exceeding 10 cm diameter 
mostly including T, as well as all those having 
distal metastasis in the lungs, liver or bones were 
classified as of large tumor volume. 
It was not possible on clinical grounds to in- 
clude vascularity as many of the cases especially 
of moderate or large tumor volume had central 
necrosis and many were either ulcerated or 
fungated. 
Methods 
Serum was separated from whole blood by 
centrifugation after clotting. Samples were 
stored at -2OOC until used. In  addition to the 
present series, data on serum levels of hCG-P in 
65 breast cancer patients have already been re- 
ported earlier by us. '' 
Antigen and Antiserum 
Highly purified hPL and hCG-@ and specific 
antisera developed in rabbit, were generously 
provided by NIAMD, National Institute of 
Health, Bethesda, U.S.A. The above hormones 
were used as a reference standard as well as for 
iodination. 
Iodination 
Carrier free 'Todine was obtained from the 
Radiochemical Centre, Amersham, England. 
The method of Greenwood, Hunter and Glover' 
as modified by Midgley' was used to iodinate 
hPL and hCG-@. To 2.5 pg of either of the 
hormone dissolved in 0.05M phosphate buffer 
(pH 7.5), lmCi "9, and 20 pg (10 pl) of chlora- 
TABLE 4. hPL and hCG-j3 Positive and Negative Patients in Different Age Groups 
hPL hCG-8 
Total no. Positive cases Negative cases Positive cases Negative cases 
Age-groups of patients (%I 8 f  (%I 8 f  (%) (%) 
3 1-40 30 4 (13) 26 (87) 2 (7) 28 (93) 
41-50 19 4 (21) 15 (79) 4 (21) 15 (79) 
51-60 13 12 (92) 2 (15) 1 1  (85) 
61-70 10 1(10) 9 (90) 4 (40) 6 (60) 
TOTAL 72 10 (14) 62 (86) 12 (17) 60 (83) 
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TABLE 5. hPL and hCG-P Positive and Negative Patients in Different Groups According to Clinical Stages 
hPL hCG-0 
Clinical Total no. of Positive cases Negative cases Positive cases Negative cases 
stage patients & (%) & ("/.I (%) (%I 
I 9 - (0) 9 (100) 2 (22) 7 (78) 
I1 21 4 (19) 17 (81) 4 (19) 17 (81) 
111 18 2 (11) 16 (89) 3 (17) 15 (83) 
IV 24 4 (17) 20 (83) 3 (13) 21 (87) 
TOTAL 72 10 (14) 62 (86) 12 (17) 60 (83) 
mine-T were added and allowed to react for 30 
seconds at room temperature. The reaction was 
stopped with the addition of 75 pg (35 pl) of 
sodium metabisulfite. Separation of iodinated 
hormone from unreacted iodine and damaged 
hormone was achieved by fractionating the reac- 
tion mixture through a column of Sephadex G- 
75, which had been equilibrated with 5% 
ovalbumin in 0.05M phosphate buffer with 0.14 
M saline (PBS). Generally 3 radioactive peaks 
were observed. The radioactive material that 
was eluted in the void volume represented dam- 
aged and aggregated hormone. The radioactive 
material that was eluted from the column at a 
position where the native hormone appears was 
used for the studies. The specific activities of 
labelled hormone ranged from 100-150 pCi per 
pg. To find out the extent of hormone damaged 
during iodination, '*1 labelled hormone was 
precipitated by excess of antibody to the same. 
It was found that 80% of the labelled hormone 
could be precipitated by the antibody. 
Assay 
All assays were carried out by the double 
antibody technique as described by Midgley. @ 
After the incubation of the antigen with the 
antiserum and labelled hormone for 48 hours at 
4OC in a final volume of 0.8 ml, second antibody 
(sheep antirabbit gamma globulin) was added. 
Incubation was continued for another 48 hours 
at 4OC. At the end of the incubation period, the 
contents of each tube were diluted to 3 ml with 
0.01M PBS containing 0.1% gelatin. Finally 
bound and free hormones were separated by 
centrifugation. The tubes were drained off and 
the amount of bound radioactive tracer was de- 
termined by gamma ray spectrometry. All se- 
rum samples were run in duplicate using 400 pl 
of serum in each assay tube. The assay was 
repeated for the confirmation of results. The 
inter-assay eoefficient of variation was lo%, and 
that of intrassay was less than 7%. Concentra- 
tion of hPL and hCG-P were expressed in terms 
of ng of standard hPL and hCG-P as supplied by 
NIAMD, Bethesda, Md. For standard curve, 
hPL as well as hCG-P were dissolved in serum 
obtained from non-pregnant control, which did 
not show any trace of either hCG-P or hPL. We 
have considered samples positive only when to- 
tal precipitable counts were less than 80%. In 
case of serum from control (negative) samples, 
total precipitable counts were 95 f 3% and 92 f 
3% for hPL and hCG-P respectively. 
RESULTS 
Figures 1 and 2 show the typical standard 
curves of hPL and hCG-P respectively. The sen- 
sitivity of the assay is up to 1 to 2 ng/ml in case 
of both the hormones. 
Table 1 shows the detection of hPL and hCG- 
P in patients with cancer of breast and allied 
non-tumorous conditions of the breast. Ten of 
72 breast cancer patients had detectable hPL 
levels in circulation, the incidence being about 
14%. In the case of hCG-P, the incidence is 
around 17% (12/72), which is very much closer 
to that observed in our earlier studies where 
9/65 were positive for hCG-8". Thus the total 
number of hCG-P positive cases from these stud- 
ies is 21/137. Serum hPL as well as hCG-Pwere 
not detectable in normal men and normal non- 
pregnant women, as well as in patients with 
other pathological conditions of breast. It was 
absent in two cases of cancer in the male breast. 
Table 2 shows the concentrations of hPL in 
individual patients. Majority of breast cancer 
patients have serum levels of 3 ng/ml. A highest 
concentration of 5 ng/ml serum was noted in 
two patients. It may be noted that hPL is se- 
creted by tumors of all sizes from small to large. 
Table 3 shows that serum hCG-P concentra- 
tion was much higher (25 ng/ml) in one patient 
as compared to the rest of positive cases. Most of 
the cases having detectable hCG-P levels fall in 
the menopausal and post-menopausal groups. 
Out  of a total of 72 breast cancer patients exam- 
ined in the present study for the presence of 
hCG-P a considerably larger number, i.e. 47, fall 
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in a group of women having menopausal or post 
menopausal history. At this stage it is difficult to 
arrive at a conclusion that breast cancer females 
at menopausal age have a larger number of 
hCG-P secreting tumors than that of younger 
age group, as the total number of patients exam- 
ined in the former group is larger than the latter 
one. In our previous studies" we observed that 
four of nine hCG-P positive serum samples were 
from women having menstrual category. It may 
be noted that the figures for incidence in our 
previous " and present studies are derived from 
retrospective investigations. 
All the cases except one with clinical stage 111 
& IV have died within 2 years. The 2-year sur- 
vival studies indicate that there was no correla- 
tion between the hPL titre as well as hCG titre 
and 2-year survival depended more on the initial 
clinical stage of the disease. However, case I in 
Table 3 who had a very high hCG-P titre (25 ng) 
died within 3 months due to development of 
tumor in the other breast. The significance of 
this is not clear as yet, and needs further work. 
Table 4 shows the number of hPL positive 
patients in various age groups. In  cases of hPL, 
the younger age groups of 31-40 and 41-50 have 
a higher number of positive cases as compared 
to those in older age groups, whereas in case of 
hCG-P the highest percentage of positive cases is 
found in the age group of 61-70. 
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to be statistically significant. - e 
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FIG. 2. Dose response curve for the human chorionic 
gonadotropin (hCG-8) 
It is interesting to note that in their studies on 
ectopic production of hCG in patients with 
primary hepatocellular carcinoma, Braunstein et 
al.' noted that the mean age of hCG positive 
group was significantly greater than that of hCG 
negative one. 
It may be noted from Table 5 that the secre- 
tion of hPL and hCG-P is detected in almost all 
the clinical stages (except in stage I for hPL) of 
the disease. 
As shown in Tables 5 and 6 there was no 
positive correlation between the serum levels of 
hCG-P and either the clinical stage of disease or 
the mass of the tumor. Thus we find five positive 
cases for hCG-8 in patients of a small tumor 
volume as well as five positive cases when the 
tumor size was almost 10 times as large. How- 
ever, in cases of hPL the highest number of posi- 
tive cases is five and is found in patients with 
large tumor volume. With moderate and small 
tumors the highest number is three and two 
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TABLE 6. Serum hPL and hCG-P Positive Patients with 
Different Tumor Volumes 
Number of Number of 
Tumor Volume hPL Positive hCG-P Positive 
~ 
Small 
Medium 
Large 
2 
3 
5 
5 
2 
5 
Only one such study in breast cancer is reported 
by Gaspard et al.' who found two cases positive 
for ectopic production of hPL. In addition to 
detecting whether some of the patients with 
breast tumors have the presence of hPL in their 
circulation, we have investigated a large number 
of breast cancer patients to find out the in- 
cidence of hPL positive patients. The incidence 
of detectable serum hPL in breast cancer was 
observed to be around 14% (10/72). Th '  is seems 
similar to that reported by Weintraub and 
Rosen '' for hepatoma (2/ 15) whereas carci- 
noma of lung had a smaller incidence (3/64). 
The range of hormone being circulated was from 
3 to 5 ng/ml serum. None of the breast cancer 
patients had as high values as reported for some 
of the patients with cancer of lung and stomach 
where concentrations are 14 and 9 ng/ml 
plasma respectively. The above finding stands 
true in case of hCG-P also. None of the breast 
cancer patients had as high concentrations of 
hCG-P as noted for bronchogenic carcinoma 
which was ranging from 75 to 40,000 ng/ml 
plasma. Is 
It is interesting to observe that none of the 
tumors secreted both hCG-P and hPL simulta- 
neously. The discordance of the hormones gives 
the possibility of having one more marker sys- 
tem for the detection of the presence of tropho- 
blastic or non-trophoblastic neoplasm. Sussman 
et al. observed that the concentration of each 
peptide, namely alkaline phosphatase, hPL and 
hCG-P, was independent of the other peptide. 
This phenomenon of discordance among the 
above mentioned hormones seems to be in strik- 
ing contrast to that of other two protein hor- 
mones ACTH and MSH. The production of 
ACTH, at least in man, appears invariably to be 
accompanied by the production of MSH. 'These 
varieties of tumors having the concordance or 
discordance of the hormones being secreted by 
them as a result of neoplastic changes might 
serve a good model system for studying the 
mechanism of the processes controlling the syn- 
thesis of these proteins. Currently the ex- 
planation for the synthesis of the hormones by 
non-endocrine tumors is uncertain. If the hy- 
pothesis' that ectopic production of the hor- 
mones represent gene derepression associated 
with malignancy holds true, then the presence of 
discordance among these proteins suggests that 
the structural genes coding for these proteins are 
not under control of a single operon. Another 
hypothesis based on current evidence has led 
to a consensus that at least in a few cases, the 
tumors might produce hormones because of ran- 
dom peptide synthesis; the hormones thus pro- 
duced may not have biological and immunolog- 
ical properties and chemical structure identical 
to that of the natural hormone. It will be of 
further interest to study whether or not the hPL 
and hCG-P detected in the patients with breast 
cancer have the biological properties and chemi- 
cal structure similar to that of native hormones. 
For many years past, the energies of many 
scientists have been devoted to attempting to 
evaluate a test or series of tests with application 
to faciliate the diagnosis of tumor or to serve as a 
guideline to the course of neoplastic disease. The 
recent evidence that human tumors secrete spe- 
cific proteins has provided a new tool to the 
problem. Carcinoembryonic antigen and alpha- 
fetoprotein represent one class of these proteins. 
The secretion of above proteins differs from that 
of placental proteins and hormones, namely al- 
kaline phosphatase, hPL and hCG. The fetal 
proteins are normally secreted by the tissue of 
origin at some time during fetal life whereas 
under normal conditions placental proteins are 
never produced by any of the tissues from which 
the tumor originates. Thus detection of these 
proteins might serve as a marker for the pres- 
ence of trophoblastic or nontrophoblastic tu- 
mors. Extensive investigation is still needed to 
assess the above possibility. 
Further studies to detect these markers in 
patients with breast tumors at a very early stage, 
and to check if there is any correlation of the 
hormonal levels with the course of the disease 
are in progress. 
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